Compile Data Set for Download or QSAR
Report error Found 116 Enz. Inhib. hit(s) with all data for entry = 8615
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408573(US10358435, Example 90 | US10358435, Example 89)
Affinity DataKi:  0.400nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408558(US10358435, Example 75 | US10358435, Example 74)
Affinity DataKi:  0.420nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408512(US10358435, Example 29)
Affinity DataKi:  0.530nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408575(US10358435, Example 92 | (S)- or (R)-6-(7-(2-Fluor...)
Affinity DataKi:  0.560nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408512(US10358435, Example 29)
Affinity DataKi:  0.630nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408573(US10358435, Example 90 | US10358435, Example 89)
Affinity DataKi:  0.630nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408564(US10358435, Example 81 | US10358435, Example 80)
Affinity DataKi:  0.930nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408571(US10358435, Example 88 | US10358435, Example 87)
Affinity DataKi:  1.20nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408542((R)- or (S)-6-(7-(2-fluoro-4- (trifluoromethyl)phe...)
Affinity DataKi:  1.30nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408582(US10358435, Example 98 | (R)- or (S)-6-(6-(2-Fluor...)
Affinity DataKi:  1.30nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408582(US10358435, Example 98 | (R)- or (S)-6-(6-(2-Fluor...)
Affinity DataKi:  1.5nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408515(6-(1-(2-(2-chloro-4-ethylphenyl) propan-2-yl)-1H-1...)
Affinity DataKi:  1.60nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408513(6-(1-(2-(2-chloro-4-(trifluoromethyl) phenyl)propa...)
Affinity DataKi:  1.70nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408518(US10358435, Example 36 | US10358435, Example 35)
Affinity DataKi:  1.70nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408564(US10358435, Example 81 | US10358435, Example 80)
Affinity DataKi:  1.70nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408571(US10358435, Example 88 | US10358435, Example 87)
Affinity DataKi:  1.80nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408580(US10358435, Example 96 | US10358435, Example 95)
Affinity DataKi:  1.80nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408498(cyclopropyl(2-fluoro-4- (trifluoromethyl) phenyl)m...)
Affinity DataKi:  2.10nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408515(6-(1-(2-(2-chloro-4-ethylphenyl) propan-2-yl)-1H-1...)
Affinity DataKi:  2.10nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408500(US10358435, Example 22 | (R)- or (S)-6-(1-(1-(2,3-...)
Affinity DataKi:  2.60nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408509(1-(2-azidopropan-2-yl)-4- ethyl-2-methylbenzene | ...)
Affinity DataKi:  3.20nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408498(cyclopropyl(2-fluoro-4- (trifluoromethyl) phenyl)m...)
Affinity DataKi:  3.40nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408500(US10358435, Example 22 | (R)- or (S)-6-(1-(1-(2,3-...)
Affinity DataKi:  3.90nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408566(US10358435, Example 83 | US10358435, Example 82)
Affinity DataKi:  4.20nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408527(US10358435, Example 44 | US10358435, Example 43)
Affinity DataKi:  4.60nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408494((E)-2-(but-1-enyl)-6-(1-(1-(2-fluoro- 4-(trifluoro...)
Affinity DataKi:  4.70nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408517(6-(1-(2-(2-chloro-4-cyclopropylphenyl) propan-2-yl...)
Affinity DataKi:  4.90nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408514(2-methyl-6-(1-(2-(2-methyl-4- (trifluoromethyl)phe...)
Affinity DataKi:  5.40nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408494((E)-2-(but-1-enyl)-6-(1-(1-(2-fluoro- 4-(trifluoro...)
Affinity DataKi:  6.5nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408488(US10358435, Example 9)
Affinity DataKi:  6.90nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408511(1-(1-azidocyclobutyl-2- chloro-4-(trifluoromethyl)...)
Affinity DataKi:  7nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408523(US10358435, Example 40 | (R)- or (S)-6-(1-(1-(2-fl...)
Affinity DataKi:  7.20nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408551((R)- or (S)-6-(5-(1-(2- chloro-4-(trifluoromethyl)...)
Affinity DataKi:  7.70nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408562(US10358435, Example 79 | US10358435, Example 78)
Affinity DataKi:  8.30nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408491(1-(1-azidoethyl)-4- (trifluoromethyl)benzene | US1...)
Affinity DataKi:  8.40nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408491(1-(1-azidoethyl)-4- (trifluoromethyl)benzene | US1...)
Affinity DataKi:  8.90nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408558(US10358435, Example 75 | US10358435, Example 74)
Affinity DataKi:  8.90nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408511(1-(1-azidocyclobutyl-2- chloro-4-(trifluoromethyl)...)
Affinity DataKi:  9nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408529((R)- or (S)-6-(5-butyl-1- (1-(2-chloro-4-(trifluor...)
Affinity DataKi:  9.20nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408488(US10358435, Example 9)
Affinity DataKi:  9.40nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408525(US10358435, Example 42 | US10358435, Example 41)
Affinity DataKi:  9.70nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408521((R)- or (S)-6-(1-(1-(2-fluoro-4- (trifluoromethyl)...)
Affinity DataKi:  10.5nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408521((R)- or (S)-6-(1-(1-(2-fluoro-4- (trifluoromethyl)...)
Affinity DataKi:  11nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408549(US10358435, Example 66 | (R)- or (S)-6-(5-(1-(2- c...)
Affinity DataKi:  15.9nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408547((R)- or (S)-6-(5-(1-(2- fluoro-4-(trifluoromethyl)...)
Affinity DataKi:  16nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408538(US10358435, Example 55 | US10358435, Example 54)
Affinity DataKi:  16.2nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408551((R)- or (S)-6-(5-(1-(2- chloro-4-(trifluoromethyl)...)
Affinity DataKi:  17nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408500(US10358435, Example 22 | (R)- or (S)-6-(1-(1-(2,3-...)
Affinity DataKi:  17.7nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408533(US10358435, Example 50 | (R)- or (S)-6-(7-(2-fluor...)
Affinity DataKi:  20.7nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM408493(1-(1-azidoethyl)-2,3- difluoro-4-(trifluoromethyl)...)
Affinity DataKi:  20.9nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 116 total ) | Next | Last >>
Jump to: